HNGE

Hinge Health runs a digital platform for musculoskeletal care, mainly serving self‑insured employers while expanding into fully insured and Medicare markets. The headline suggests the company’s growth may be overvalued.

Barclays maintains an Overweight stance on Hinge Health and raises its price target to $110 from $100. This indicates the bank sees continued upside for the stock.

Hinge Health’s revenue jumped 53%, margins improved, and free cash flow grew, but the stock’s valuation appears stretched.